0000000001040560
AUTHOR
Götz M. Richter
Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions : results of a multicenter, single-blind, interindividual, randomized clinical phase III trial
The purpose of this phase III clinical trial was to compare two different extracellular contrast agents, 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine, for magnetic resonance imaging (MRI) in patients with known or suspected focal renal lesions. Using a multicenter, single-blind, interindividual, randomized study design, both contrast agents were compared in a total of 471 patients regarding their diagnostic accuracy, sensitivity, and specificity to correctly classify focal lesions of the kidney. To test for noninferiority the diagnostic accuracy rates for both contrast agents were compared with CT results based on a blinded reading. The average diagnostic accuracy across the three bli…
Therapeutische Alternativen beim fortgeschrittenen Nierentumor
Metastasierte Nieren-Carcinome stellen ein ungelostes therapeutisches Problem dar. Seit uber 20 Jahren werden in die Immuntherapie immer wieder Erwartungen gesetzt, die sich letztlich nicht erfullt haben. Die Liste immunologischer Therapieansatze ist lang und reicht von der BCG-Therapie bis zu den verschiedenen Interferonen. Damit konnten zwar in wenigen Fallen komplette Metastasenregressionen erzielt werden. Ein therapeutischer Durchbruch war es jedoch nicht.